NCT03041025View on ClinicalTrials.gov

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

July 7, 2020

Study Completion Date

July 7, 2020

Conditions
Scleroderma, Systemic
Interventions
DRUG

GSK2330811

GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.

DRUG

Placebo

Normal saline (0.9 percent weight per volume sodium chloride).

Trial Locations (14)

21224

GSK Investigational Site, Baltimore

48109

GSK Investigational Site, Ann Arbor

60611

GSK Investigational Site, Chicago

90045

GSK Investigational Site, Los Angeles

94304

GSK Investigational Site, Stanford

02118

GSK Investigational Site, Boston

M5T 3L9

GSK Investigational Site, Toronto

6525 GA

GSK Investigational Site, Nijmegen

M6 8HD

GSK Investigational Site, Salford

L9 7AL

GSK Investigational Site, Liverpool

B15 2TH

GSK Investigational Site, Birmingham

DD1 9SY

GSK Investigational Site, Dundee

LS7 4SA

GSK Investigational Site, Leeds

NW3 2QG

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03041025 - Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis | Biotech Hunter | Biotech Hunter